Alkem’s US Business Doubles And Continues To Grow

As Company Received 10 ANDA Approvals In Q4 FY21

India’s Alkem Laboratories has reported double-digit growth in its US business for financial year 2021, after seeing its US business double in four years. The company also saw recovery in its domestic business on the back of robust growth delivered by its generics business. 

Indian Rupee
Alkem’s domestic business continues to recover and grow significantly • Source: Alamy

Alkem Laboratories Ltd has seen its US business double in size over the past four years, from FY17 to FY21, “led by new product launches and market share gain in existing products.” The Indian company observed that in the fourth quarter of its most recent financial year alone, its US sales contributed 25.1% of the company’s total. However, Alkem acknowledged that it saw its US sales drop by 10.4% to INR5.4bn ($75m) for the quarter ending 31 March 2021.

On a yearly basis, Alkem reported growth of 11.4% in its US business to INR24.5bn in FY21, compared to INR22.0bn...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin